Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

On Research Review Boards, Conflict-of-Interest Reporting Improves

Kathryn Doyle  |  July 16, 2015

(Reuters Health)—Many doctors who serve on hospital panels overseeing the ethics and safety of human research trials have industry relationships that may compromise their objectivity, but reporting these conflicts has become more common over the past 10 years, according to a new study.

Physicians who serve on so-called institutional review boards (IRBs) may also be providing biotechnology, drug and device companies with services or expertise in return for payment.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“(IRBs) approve and oversee the studies which are often funded by pharmaceutical companies,” said lead author Eric G. Campbell of Massachusetts General Hospital in Boston. “People who serve on these committees may have financial relationships with companies whose research they oversee, and that has potential positive and potential negative consequences.”

Having a relationship with the company funding the research may mean you have more experience with the area of study and can be an expert judge of whether a study protocol is safe and ethical, but it could also bias your decision in favor of the company, Campbell told Reuters Health by phone.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“It’s important to disclose their relationships and also to not vote on protocols for which they have conflicts,” he said. “Universities have gotten much better at disclosing conflicts,” but many physicians still vote on protocols they have a relationship with, he said.

For the new study, researchers replicated a 2005 survey of IRB members, mailing surveys to 115 research-intensive medical schools and teaching hospitals. They received responses from 493 members in 2014, slightly more than had answered in 2005.

About a third of IRB members had some kind of industry relationship in 2005 and 2014, but the percentage who felt another member did not properly disclose their financial relationships in the past year decreased from 10.8 percent to 6.7 percent, the researchers reported in JAMA Internal Medicine.

More than half of physicians in 2014 said their institution had a formal written definition of a conflict of interest, compared to fewer than half of those who responded in 2005.

The percentage who felt another IRB member had presented a protocol in a biased manner because of their industry relationship decreased, as did the percentage who felt pressure to approve a protocol they felt was not ready.

But the percentage of members who voted on a study protocol with which they had a conflict of interest did not decrease significantly over time.

Academic medical centers could still improve how they clarify and publicize their conflict of interest policies, as many physicians are still in the dark about their institution’s policy, Campbell said.

Patients who enroll in clinical trials, whether they know it or not, need to be able to trust an IRB to make sure the trial is ethical and safe, he said.

“Clinical research is so important—there are so many serious diseases and health conditions that we must understand to improve the health of the public,” said Dr. Laura Weiss Roberts of Stanford University School of Medicine in California, who wrote a commentary on the new results. “For this reason, a strong IRB is really the ‘best friend’ to great clinical researchers.”

“Professionals should, in my view, engage in many different kinds of activities that make the best use of their expertise in society,” which generates potential conflicts, she told Reuters Health by email.

Conflicts of interest should not be misunderstood or vilified, she said.

“Some conflicts are incompatible with certain roles and activities, but many role conflicts and resulting conflicts of interest can be managed very effectively,” Roberts said.

Page: 1 2 | Multi-Page
Share: 

Filed under:EthicsProfessional Topics Tagged with:Ethicsphysician

Related Articles

    Ethics Forum: Is a Conflict-of-Interest Slide Enough?

    December 18, 2018

    TarikVision / shutterstock.com We have all been to numerous lectures, grand rounds and other continuing medical education activities where the speaker, prepared and poised at the podium, begins his lecture with a title slide. Soon after, we see the ubiquitous conflicts of interest slide, which lists the invited speaker’s research funding, his consulting activities and…

    Conflicts of Interest in Guideline Development: What to Do When Everyone Has a Conflict

    March 12, 2023

    Avoiding real and apparent conflicts of interest is a fundamental principle of guideline development, but what should we do when every thought leader is conflicted? An example of this conundrum in rheumatology has been the ACR’s ongoing effort to establish guidelines for the management of lupus nephritis, which has been stymied by the fact that…

    Ethics Forum: What Are Conflicts of Interest?

    October 17, 2019

    Results from an ethics survey presented to attendees at the 2018 ACR/ARHP Annual Meeting highlight the complexities and challenges of assessing potential conflicts of interest.

    Physician–Industry Relationships

    July 1, 2009

    The ACR’s strict ethical policy guides relationships with pharmaceutical and medical device manufacturers

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences